These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31143480)

  • 21. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC.
    Arijs I; De Hertogh G; Lemmens B; Van Lommel L; de Bruyn M; Vanhove W; Cleynen I; Machiels K; Ferrante M; Schuit F; Van Assche G; Rutgeerts P; Vermeire S
    Gut; 2018 Jan; 67(1):43-52. PubMed ID: 27802155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
    Coletta M; Paroni M; Alvisi MF; De Luca M; Rulli E; Mazza S; Facciotti F; Lattanzi G; Strati F; Abrignani S; Fantini MC; Vecchi M; Geginat J; Caprioli F
    J Crohns Colitis; 2020 Sep; 14(9):1190-1201. PubMed ID: 32100016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
    Battat R; Ma C; Jairath V; Khanna R; Feagan BG
    Drug Saf; 2019 May; 42(5):617-632. PubMed ID: 30830573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.
    Smith MA; Mohammad RA
    Ann Pharmacother; 2014 Dec; 48(12):1629-35. PubMed ID: 25186623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study.
    Macaluso FS; Fries W; Renna S; Viola A; Muscianisi M; Cappello M; Guida L; Siringo S; Camilleri S; Garufi S; Privitera AC; Belluardo N; Giangreco E; Bertolami C; Vassallo R; Rizzuto G; Orlando R; Ventimiglia M; Orlando A;
    United European Gastroenterol J; 2020 Nov; 8(9):1045-1055. PubMed ID: 32772830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.
    Garnock-Jones KP
    BioDrugs; 2015 Feb; 29(1):57-67. PubMed ID: 25502899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the integrin α4β7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis.
    Wittner M; Schlicker V; Libera J; Bockmann JH; Horvatits T; Seiz O; Kummer S; Manthey CF; Hüfner A; Kantowski M; Rösch T; Degen O; Huber S; Eberhard JM; Schulze Zur Wiesch J
    PLoS One; 2019; 14(7):e0220008. PubMed ID: 31356607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vedolizumab response in inflammatory bowel disease. Two years of follow-up.
    Del Pino Bellido P; Belvis Jiménez M; Castro Laria L; Maldonado Pérez MB; Sáez Díaz A; Caunedo Álvarez Á; Argüelles-Arias F
    Rev Esp Enferm Dig; 2020 Jul; 112(7):555-558. PubMed ID: 32579005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fatal ulcerative enteritis of the small intestine in a patient with ulcerative colitis treated with vedolizumab.
    Monasterio C; Schmitt-Gräff A; Pohl M; Truschel T; Warnatz K; Kreisel W; Thimme R; Hasselblatt P
    Z Gastroenterol; 2017 Oct; 55(10):1014-1020. PubMed ID: 28655067
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis.
    Pellet G; Stefanescu C; Carbonnel F; Peyrin-Biroulet L; Roblin X; Allimant C; Nachury M; Nancey S; Filippi J; Altwegg R; Brixi H; Fotsing G; de Rosamel L; Shili S; Laharie D;
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):494-501. PubMed ID: 30213584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease.
    Kotze PG; Ma C; Almutairdi A; Al-Darmaki A; Devlin SM; Kaplan GG; Seow CH; Novak KL; Lu C; Ferraz JGP; Stewart MJ; Buresi M; Jijon H; Mathivanan M; Heatherington J; Martin ML; Panaccione R
    Aliment Pharmacol Ther; 2018 Sep; 48(6):626-637. PubMed ID: 30063077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience.
    Kopylov U; Ron Y; Avni-Biron I; Koslowsky B; Waterman M; Daher S; Ungar B; Yanai H; Maharshak N; Ben-Bassat O; Lichtenstein L; Bar-Gil Shitrit A; Israeli E; Schwartz D; Zittan E; Eliakim R; Chowers Y; Ben-Horin S; Dotan I
    Inflamm Bowel Dis; 2017 Mar; 23(3):404-408. PubMed ID: 28178003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists.
    De Vos M; Dhooghe B; Vermeire S; Louis E; Mana F; Elewaut A; Bossuyt P; Baert F; Reenaers C; Van Gossum M; Macken E; Ferrante M; Hindryckx P; Dewit O; Holvoet T; Franchimont D;
    United European Gastroenterol J; 2018 Apr; 6(3):439-445. PubMed ID: 29774158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis?
    Rodríguez-Lago I; Benítez JM; Sempere L; Sáez-González E; Barreiro-de Acosta M; de Zárate JO; Cabriada JL
    J Clin Apher; 2019 Dec; 34(6):680-685. PubMed ID: 31518013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2.
    Feagan BG; Schwartz D; Danese S; Rubin DT; Lissoos TW; Xu J; Lasch K
    J Crohns Colitis; 2018 Apr; 12(5):621-626. PubMed ID: 29471381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease?
    Gilroy L; Allen PB
    Clin Exp Gastroenterol; 2014; 7():163-72. PubMed ID: 24899819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
    Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report.
    Zhang J; Liu MH; Gao X; Dong C; Li YX
    World J Clin Cases; 2022 Feb; 10(5):1716-1722. PubMed ID: 35211614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
    Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and Efficacy of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in Patients With Refractory Inflammatory Bowel Disease.
    Christensen B; Gibson PR; Micic D; Colman RJ; Goeppinger SR; Kassim O; Yarur A; Weber CR; Cohen RD; Rubin DT
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):486-493. PubMed ID: 29751166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.